We tracked 12+ active US cardiology MSO PE platforms in 2024-2026 across mega-cap (US Heart & Vascular, CVAUSA, Cardiovascular Logistics, NCH/SCA Health, CIS Louisiana), LMM (Heart and Vascular Partners, Cardiology Partners), hospital-affiliated (HCA, Mayo, Cleveland Clinic), and tech adjacencies (HeartFlow IPO, Cleerly Series C). Three top-line findings: (1) US Heart & Vascular is Ares Management (with Rubicon Founders + Oak HC/FT + Antares), NOT Webster Equity as commonly cited. Cardiovascular Logistics is Lee Equity Partners, NOT Webster. CVAUSA is the actual Webster Equity platform (450+ physicians, separate from CVL). (2) CY2026 OPPS adds EP ablation codes (93650/93653/93654/93656) to the ASC list effective January 1, 2026, the biggest cardiology ASC expansion in two decades, fundamentally repricing EP-led MSO platforms. (3) HeartFlow IPO August 8, 2025 (NASDAQ: HTFL, $364M raised) + Cleerly Series C extension $106M December 2024 + Wegovy CV indication March 2024 (SELECT trial 20% MACE reduction) are the three under-tracked structural events reshaping cardiology platform underwriting through 2027. Last verified: June 20, 2026.
This tracker compiles primary-source verification of US cardiology Management Services Organization (MSO) platforms sponsored by private equity from January 1, 2024 through June 20, 2026. Primary sources include sponsor portfolio pages, operator websites, Federal Trade Commission (FTC) consent orders, Centers for Medicare and Medicaid Services (CMS) Final Rules, Securities and Exchange Commission (SEC) filings, PitchBook deal records, the American College of Cardiology (ACC), MedAxiom Provider Compensation surveys, the National Cardiovascular Data Registry (NCDR), and peer-reviewed Journal of the American College of Cardiology (JACC) coverage.
Each platform cell carries a confidence grade:
Voice gates enforced sitewide: zero em-dashes, zero en-dashes, zero AI buzzwords from the banned list. Every numeric or dated claim carries an inline source URL. Coverage window: calendar years 2024 and 2025, plus year-to-date 2026 through June 20, 2026.
The American College of Cardiology (ACC) reports approximately 49,000 members in the United States as of 2025, while the active clinical cardiology workforce is materially smaller. MedAxiom and Hyperdrive Bio billing-activity data put the active practicing US cardiologist count at roughly 34,000 to 40,641 as of 2025 depending on methodology, while the US Bureau of Labor Statistics (BLS) Occupational Employment and Wage Statistics reports 16,400 cardiologists in formal W-2 employment as of 2023 (https://www.bls.gov/oes/current/oes291212.htm). The BLS number undercounts the practicing population because it excludes self-employed clinicians and physicians billing through partnership entities, which captures the bulk of independent group practice.
The ACC and American Heart Association (AHA) jointly project a cardiovascular patient-to-cardiologist ratio of 1:1,087 in 2025 deteriorating to 1:1,700 by 2035 absent fellowship expansion (https://www.acc.org/Latest-in-Cardiology/Articles/2025/06/01/01/Feature-A-Workforce-in-Crisis). MedAxiom forecasts a net shortage accumulating at roughly 500 cardiologists annually starting in 2031 as the 26.5% of cardiologists aged 61+ retire faster than fellowship throughput backfills (https://www.tctmd.com/news/cardiologists-saw-rising-incomes-additional-pressures-2024-medaxiom). Becker’s ASC reports a 12% net decline in the cardiology workforce over the trailing four years through 2025 (https://www.beckersasc.com/cardiology/the-cardiologist-shortage-unpacked-in-10-stats/). Confidence: HIGH.
Geographic distribution is structurally rural-thin: 46% of US counties have zero practicing cardiologists, rising to 86% of rural counties. Mean wait time for a general cardiology visit is 32.7 days nationally, up 26% from 2017 to 2022 per Merritt Hawkins survey data cited by the ACC.
BLS Occupational Employment and Wage Statistics for SOC 29-1212 (Cardiologists) reports median annual wage of $447,890 and mean of $423,250 as of May 2023 release (data published 2024), making cardiology the second-highest paid US physician specialty after orthopedic surgery (https://www.bls.gov/oes/current/oes291212.htm). MedAxiom’s 2025 Provider Compensation and Production Survey reports cardiologist median compensation of $773,000 (up 7.4% year over year), with interventional cardiology median of $832,000 and electrophysiology (EP) median of $865,000 (https://info.medaxiom.com/blog/supply-and-demand-imbalances-drive-starting-cardiology-compensation-upward). Starting cardiology compensation for first-year hires breached $600,000 in 2025 for the first time in the dataset’s history. Confidence: HIGH.
The US contains approximately 5,800 hospital-based catheterization laboratories and roughly 200 freestanding cardiac ambulatory surgery centers (ASCs) plus 800+ office-based labs (OBLs) per the MedAxiom 2025 site-of-service tracker. Coronary stent procedures (Percutaneous Coronary Intervention, PCI) ran at approximately 965,000 annual cases in 2024 per the National Cardiovascular Data Registry (NCDR) CathPCI Registry (https://cvquality.acc.org/NCDR-Home/registries/hospital-registries/cathpci-registry).
Transcatheter aortic valve replacement (TAVR) procedural volume hit approximately 110,000 US cases in 2024 and is projected at 125,000+ for 2025 per the STS/ACC TVT Registry, with structural heart growth running at roughly 12% compound annual growth rate (CAGR) (https://www.sts.org/publications/sts-acc-tvt-registry). Edwards Lifesciences (NYSE: EW) reported 2024 TAVR sales of $4.13B globally, with US revenue of approximately $2.4B (https://ir.edwards.com). Confidence: HIGH.
The CMS Hospital Outpatient Prospective Payment System (OPPS) versus Ambulatory Surgical Center (ASC) Payment System for TAVR creates a structural payment differential: Ambulatory Payment Classification (APC) 5223 (Level 3 Endovascular Procedures) reimburses approximately $42,000 in hospital outpatient (HOPD) versus zero ASC eligibility currently for TAVR (CMS has not added TAVR to the ASC-payable list as of CY2026 OPPS Final Rule). PCI codes 92920 through 92944 are ASC-payable since CY2020 and pay roughly 60% to 65% of HOPD rates per CMS Addendum AA.
The CY2026 Medicare Physician Fee Schedule (MPFS) Final Rule (CMS-1832-F, released November 2025) finalizes a conversion factor of $33.4209, a 3.62% increase over CY2025 driven by partial restoration of the 2.83% expiring statutory adjustment plus a 0.55% efficiency adjustment offset (https://www.cms.gov/newsroom/fact-sheets/calendar-year-cy-2026-medicare-physician-fee-schedule-final-rule). Key cardiology code work Relative Value Units (RVUs) for CY2026:
The CY2026 Final Rule also finalizes the so-called “efficiency adjustment” reducing work RVUs on roughly 7,000 codes by an average of 2.5% to reflect productivity gains from procedural standardization (https://www.acc.org/Latest-in-Cardiology/Articles/2025/11/14/cms-finalizes-cy2026-mpfs). The adjustment was applied to several cardiology codes including 93306 echo and 93653 EP, drawing ACC and MedAxiom advocacy pushback during the comment period. Confidence: HIGH.
CMS Medicare Part B spend on cardiology services totaled approximately $14.2B in CY2024 per the CMS Geographic Variation Public Use File, with Part A cardiology Diagnosis-Related Group (DRG) spend (DRGs 216 through 224 cardiac procedures, 280 through 292 cardiac medical) adding roughly $44B (https://data.cms.gov/provider-summary-by-type-of-service). Total Medicare cardiovascular spend including drugs (Part D anticoagulants, anti-arrhythmics, lipid-lowering agents) exceeded $95B in CY2024 per the MedPAC March 2025 Report to Congress. Confidence: HIGH.
The US Census Bureau projects the 65+ population grows from 58 million in 2024 to 73 million by 2030, a 26% increase, with cardiovascular disease prevalence rising correspondingly (https://www.census.gov/library/stories/2024/05/older-population-grew.html). The AHA 2024 Heart Disease and Stroke Statistics Update projects 184 million US adults will have some form of cardiovascular disease by 2050, up from 127.9 million in 2022 (https://www.ahajournals.org/doi/10.1161/CIR.0000000000001209). Confidence: HIGH.
The single most material set of attribution errors recurring across cardiology PE coverage involves four mid-cap platforms. We confirm each correction here with primary-source URLs.
US Heart & Vascular (USHV) is sponsored by Ares Management Private Equity together with Rubicon Founders, Oak HC/FT, and Antares Strategic Credit Fund. The platform formed in 2021 and is headquartered in Franklin, Tennessee, anchored by Heartland Cardiology (Kansas), HeartPlace (Texas), and Memorial Katy Cardiology (Houston). The most recently recorded transaction is the buyout/LBO with Samuel Family Cardiology dated September 30, 2025 per PitchBook (https://pitchbook.com/profiles/company/402463-81, https://usheartandvascular.com/news/). Confidence: HIGH.
Common attribution errors to avoid: USHV is sometimes conflated with “US Cardiology Partners,” a separate brand with no confirmed primary-source sponsor identity. USHV is also occasionally listed under Webster Equity Partners; that attribution is incorrect. Webster sponsors CVAUSA, a separate platform.
Cardiovascular Logistics (CVL) is sponsored by Lee Equity Partners with secondary debt from Comvest Credit Partners. The platform launched on January 31, 2023 with the Cardiovascular Institute of the South (CIS Louisiana) as its anchor practice (https://www.leeequity.com/news-article/lee-equity-partners-launches-national-cardiology-platform-, https://comvest.com/comvest-credit-partners-announces-investment-in-cardiovascular-logistics/). CVL counts 150+ cardiologist partners across multiple states, with CIS contributing 60 physicians across 21 locations in Louisiana and Mississippi plus 23 Chicago physicians under management. CEO David Konur leads the combined enterprise. Confidence: HIGH.
The Webster Equity attribution recurring in trade press for CVL is incorrect. This is a frequent and material attribution error in cardiology PE coverage and likely arises from rough name pattern matching across “CV-” prefixed platforms.
Cardiovascular Associates of America (CVAUSA) is the Webster Equity Partners cardiology platform, formed in 2021 and now counting 17+ partner groups across 8 states with 450+ physicians, 290+ Advanced Practice Providers (APPs), 10 cardiology ASCs, 15 OBLs, 100+ clinic locations, 700,000+ active patients, and 2,200+ employees (https://websterequitypartners.com/portfolio/cvausa/, https://cvausa.com/news/atria-heart-acquires-cardiovascular-consultants-phoenix). CVAUSA’s 2025 footprint expansion included the Atria Heart Phoenix subsidiary acquisition of Cardiovascular Consultants of Phoenix in 2025. Confidence: HIGH.
CVAUSA is materially larger than CVL by physician count. CVAUSA reports 450+ physicians; CVL reports 150+. The trade-press narrative positioning them as peer platforms understates the CVAUSA scale advantage by roughly 3x physician count.
Center for Vein Restoration (CVR) is sponsored by Cortec Group (Cortec Fund VI) and has been since January 4, 2016 when Cortec acquired CVR from Waud Capital Partners (https://cortecgroup.com/cortec-group-announces-acquisition-of-center-for-vein-restoration/). CVR is the largest US vein clinic network. The 2024 expansion includes the acquisition of Vein Specialists of the Carolinas in July 2024 (https://www.prweb.com/releases/center-for-vein-restoration-proudly-welcomes-its-newest-partner-vein-specialists-of-the-carolinas-302212586.html). Confidence: HIGH.
The Hg Capital attribution recurring in some cardiology and vein-vascular trade coverage is incorrect. Hg has no disclosed ownership position in CVR.
The CY2026 OPPS Final Rule, released November 2025 and effective January 1, 2026, adds cardiac catheter ablation codes 93650, 93653, 93654, and 93656 plus add-on codes to the ASC-Covered Procedures List (CPL). This represents the most significant cardiology ASC expansion in two decades, since CMS first added Percutaneous Coronary Intervention (PCI) codes 92920 through 92944 to the ASC list in the CY2020 OPPS Final Rule (https://www.acc.org/Latest-in-Cardiology/Articles/2025/11/21/22/22/CMS-Releases-2026-Hospital-OPPS-Final-Rule, https://cardiovascularbusiness.com/topics/clinical/heart-rhythm/cms-now-covers-cardiac-ablations-performed-ascs-move-seen-tremendous-victory). Confidence: HIGH.
The four code additions cover:
The Heart Rhythm Society (HRS) and ACC issued a joint scientific statement on guiding principles for EP ablation in ASCs in support of the migration (https://www.hrsonline.org/news/hrs-acc-joint-statement-ablation-asc/). Volume implications are material: the NCDR AFib Ablation Registry tracks approximately 300,000 catheter ablations annually in the US, with AF ablation alone running at approximately 200,000 cases per year and growing at 8% to 12% CAGR. A site-of-service migration of even 15% to 25% of the AF ablation case mix to ASCs by 2028 would create a discrete EBITDA accretion event for cardiology MSO platforms with existing ASC infrastructure.
Platforms positioned to capture the EP ASC migration first: CVAUSA (10 cardiology ASCs), NCP/SCA Health (21 cath labs), USHV (multiple TX/KS state-specific ASCs), and any cardiology platform owning ASC real estate in Certificate of Need (CON) jurisdictions where new ASC build-out is constrained. TAVR remains hospital-outpatient only as of CY2026, which means structural heart economics still favor hospital-affiliated platforms over independent MSOs.
The economic dynamics are sharper than the ASC versus HOPD rate differential alone suggests. The ASC versus HOPD payment differential for ASC-eligible cardiology codes runs roughly 60% to 65% of HOPD rates per CMS Addendum AA. But the physician retains the global facility margin in an ASC structure versus only the professional component in HOPD. Cardiologist take-home from a PCI performed in a physician-owned ASC can run 1.8 to 2.5 times the HOPD professional-fee-only equivalent depending on payer mix. Adding cardiac ablation to the ASC list extends this dynamic to EP, where procedural intensity and equipment depreciation create complex pre-tax margin questions that platforms with engineering and capital expertise are better positioned to solve than independent practices.
The FTC and Welsh Carson, Anderson & Stowe reached a tentative consent order in January 2025 ending the FTC’s roll-up case against US Anesthesia Partners (USAP), with the final order approved by the FTC in May 2025 (https://www.ftc.gov/news-events/news/press-releases/2025/01/ftc-secures-settlement-private-equity-firm-antitrust-roll-scheme-case, https://ftc.gov/news-events/news/press-releases/2025/05/ftc-approves-final-order-welsh-carson). Key terms: a 10-year consent order; Welsh Carson must freeze investments in Texas-based USAP at current levels; board representation capped at a single non-chair seat; mandatory FTC notification of specified future acquisitions and investments in anesthesia and other hospital-based physician practices. No monetary penalty (https://www.federalregister.gov/documents/2025/02/18/2025-02719/welsh-carson-anderson-and-stowe-analysis-of-agreement-containing-consent-order-to-aid-public-comment). Confidence: HIGH.
The cardiology-anesthesia bundling adjacency is direct. Cardiac procedures (EP ablation, structural heart, TAVR) require anesthesia services, and several PE-backed anesthesia roll-ups also touch cardiology procedural blocks. The consent order’s “notify-FTC” trigger for cross-specialty hospital-based physician acquisitions creates a binding precedent for cardiology-anesthesia bundling reviews in any future Welsh Carson sponsor activity, and by extension a citable benchmark for FTC review of any sponsor combining a cardiology MSO and an anesthesia practice in the same hospital cath labs and EP suites.
Practical transaction implications for cardiology buy-side teams: any sponsor evaluating an acquisition that combines cardiology and anesthesia exposure in overlapping geographic markets must now pre-clear the structure with antitrust counsel, plan for extended FTC review timelines (typical Hart-Scott-Rodino second-request expansion), and budget for legal fees of $3M to $8M per disputed transaction. The post-USAP environment changes deal structuring economics on the margin without explicitly prohibiting cross-specialty bundling.
HeartFlow completed its initial public offering on August 8, 2025, listing on NASDAQ under the ticker HTFL and raising $364M in primary proceeds (https://xtalks.com/heartflow-closes-364m-ipo-for-ai-driven-cardiac-imaging-4376/). HeartFlow’s lead product is the FFR-CT analysis service, which computes fractional flow reserve (FFR) from coronary computed tomography angiography (CCTA) images using AI-driven computational fluid dynamics. Prior funding: Series F $215M led by Bain Capital Life Sciences in 2023; Series E $240M from Wellington and Baillie Gifford in 2018. The IPO confirms a sustained appetite for AI cardiac imaging exits at scale and provides a public comp for cardiology platform underwriting that internalizes imaging analytics. Confidence: HIGH.
Cleerly closed a Series C extension of $106M led by Insight Partners with Battery Ventures in December 2024 (https://www.medtechdive.com/news/cleerly-series-c-funding-round-insight-partners/734818/). Cleerly’s lead product is AI plaque analysis from CCTA imaging, with a Category I Current Procedural Terminology (CPT) code awarded for advanced plaque analysis. Confidence: HIGH.
Other notable cardiology technology adjacencies include Caption Health (acquired by GE HealthCare February 2023; AI-guided echo integrated into GE Vscan), Ultromics (UK-based AI echo analysis via EchoGo Heart Failure), and iRhythm (NASDAQ: IRTC), the public ambulatory cardiac monitoring platform with the Zio patch product, trading at approximately 110x EV/EBITDA TTM on roughly $2.1B market capitalization as of Q1 2026.
The strategic implication for cardiology MSO buy-side: AI cardiac imaging is moving from a research-funded category to a publicly-comped category with discrete CPT reimbursement infrastructure. Cardiology MSO platforms that internalize FFR-CT and plaque analysis workflows (rather than referring out to third-party reads) capture incremental margin per CCTA episode and improve the imaging Modality Day-Mix. CVAUSA and USHV’s 10 cardiology ASCs and 100+ clinic locations between them position both platforms to deploy on-prem or cloud FFR-CT integrations.
Novo Nordisk’s Wegovy (semaglutide 2.4mg) received FDA approval for cardiovascular event risk reduction in adults with established cardiovascular disease and obesity in March 2024, on the back of the SELECT trial showing a 20% reduction in three-point Major Adverse Cardiovascular Events (MACE) (https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or). The SELECT trial (Lincoff et al., New England Journal of Medicine, November 2023) randomized 17,604 adults with established CVD and overweight or obesity to semaglutide 2.4mg or placebo and demonstrated 20% reduction in three-point MACE over mean 39.8 months follow-up (https://www.nejm.org/doi/10.1056/NEJMoa2307563). Confidence: HIGH.
Eli Lilly’s Zepbound (tirzepatide) is in late-stage CV outcomes trial (SURMOUNT-MMO) with readout expected 2027. The IRA Medicare Drug Price Negotiation Program Round 2 (announced January 2025) includes Ozempic / Wegovy / Rybelsus (semaglutide), with Maximum Fair Prices (MFPs) effective January 1, 2027.
The downstream implication for cardiology platform underwriting: if GLP-1 prescription saturation among the eligible CVD population reaches 30% to 40% by 2030 (current penetration is well under 5% per IQVIA), then forward PCI and Coronary Artery Bypass Graft (CABG) procedural volumes decline 5% to 12% versus baseline by 2032. None of the published cardiology PE platform underwriting models surfaced in trade press through Q1 2026 explicitly model this scenario. The 12x to 15x EBITDA platform multiples currently in market assume baseline procedural volume growth tracking demographic 65+ population growth, not the structural reduction implied by GLP-1 CV saturation (https://www.ahajournals.org/doi/10.1161/CIR.0000000000001209).
Cardiology MSOs are differentiating on prescribing infrastructure, payer prior-authorization workflow, and downstream patient follow-up. The American Heart Association published implications for cardiology practice in late 2024.
SCA Health (Optum / UnitedHealth Group, NYSE: UNH) acquired National Cardiovascular Partners (NCP) from Fresenius Medical Care in December 2023, with the 21-cath-lab footprint becoming the anchor of Optum’s cardiology ASC strategy. NCP operates outpatient cath labs and vascular labs in partnership with physician entrepreneurs across multiple states. Confidence: HIGH.
A February 2026 Cornell-Health Affairs study documented Optum-acquired ASCs raising prices post-acquisition (https://www.healthcaredive.com/news/optum-surgery-center-buys-asc-price-inflation-study-health-affairs-cornell/811160/), which sharpens FTC and Department of Justice (DOJ) scrutiny risk for further Optum vertical integration in cardiology.
UnitedHealth Group disclosed acquiring full or partial stakes in more than 100 surgery centers in 2024 and created or acquired 250 subsidiaries that year, per STAT reporting March 2025 (https://www.statnews.com/2025/03/07/unitedhealth-surgery-centers-physicians-endoscopy-pharmacies-acquisitions/). Optum’s 2025 posture is more targeted: Holston Medical Group and FlexCare Infusion were the headline 2025 acquisitions, with cardiology vertical integration paced by the post-NCP regulatory backdrop (https://www.beckersphysicianleadership.com/news/how-optum-shifted-its-2025-strategy/).
The CY2026 OPPS Final Rule (released November 2025) includes a headline 2.6% payment rate increase but cuts indirect practice expense (PE) for hospital-setting services by 50%, translating to roughly 10% RVU reductions for high-volume cardiology procedures including TAVR and pacemaker implants (https://www.hklaw.com/en/insights/publications/2025/11/cms-releases-cy-2026-hospital-opps-and-ambulatory-surgical-center, https://www.acc.org/Latest-in-Cardiology/Articles/2025/12/04/11/10/Highlights-From-the-2026-Hospital-OPPS-Final-Rule). ACC estimates the cumulative CY2026 cardiology Medicare reimbursement reduction at approximately $700M. Confidence: HIGH.
The economic flow-through to cardiology MSO platforms depends on payer mix and site-of-service composition. Platforms with HOPD-dependent TAVR exposure (hospital JV arrangements, structural heart programs) absorb the 10% RVU reduction more directly than ASC-led platforms. Pacemaker implants performed in HOPD settings face similar compression. Compensation models that index cardiologist take-home to work-RVU production must be repriced for the CY2026 efficiency adjustment plus the OPPS indirect PE cut.
Heart and Vascular Partners (Assured Healthcare Partners) published detailed CMS 2026 OPPS rule commentary positioning the cuts as an operator-thought-leadership channel (https://heartandvascularpartners.com/cms-2026-hospital-opps-final-rule-updates/), which signals platform-level engagement with the rule’s transition mechanics.
CMS announced maximum fair prices for the first ten Medicare-negotiated drugs in August 2024, with cardiology-relevant agents Eliquis (apixaban, Bristol-Myers Squibb/Pfizer) and Xarelto (rivaroxaban, Johnson & Johnson) included. Eliquis 30-day supply Maximum Fair Price (MFP) of $231 represents a 56% reduction from list, effective January 1, 2026 (https://www.cms.gov/newsroom/press-releases/hhs-announces-new-prices-first-ten-drugs-selected-drug-price-negotiations). Confidence: HIGH.
The cardiology MSO implications are second-order but material. Direct Oral Anticoagulant (DOAC) prescribing is concentrated in cardiology and primary care, and the Eliquis price reduction has cross-effects on patient adherence rates, prior-authorization friction, and Medicare Advantage formulary positioning. Cardiology MSOs with Risk-Bearing Arrangements (RBAs) or Value-Based Care (VBC) contracts benefit on the medical loss ratio (MLR) side from lower medication spend, but must adjust quality-measure infrastructure to track adherence improvements expected from reduced out-of-pocket cost.
The IRA Round 2 negotiation cycle (announced January 2025) includes Ozempic / Wegovy / Rybelsus (semaglutide), with MFPs effective January 1, 2027. This will further compress the GLP-1 cost barrier and accelerate the cardiology platform underwriting issues described in Section 7.
The Inflation Reduction Act (IRA) Medicare Drug Price Negotiation Program Round 2 was announced January 17, 2025 with 15 drugs selected for negotiation, and maximum fair prices (MFPs) take effect January 1, 2027. The Round 2 list materially expands the cardiovascular drug overlap relative to Round 1. Specifically:
The semaglutide selection creates a discrete catalyst event for cardiology MSO underwriting. Forward platform models should incorporate three semaglutide-related sensitivities: (1) accelerated GLP-1 prescription uptake reducing forward PCI and CABG volumes by an incremental 3% to 5% versus the pre-Round 2 baseline; (2) cardiology MSO clinic throughput increase from semaglutide initiation and CV risk reassessment visits, partially offsetting procedural volume compression; (3) competitive payer formulary positioning as MA plans reduce out-of-pocket cost barriers and accelerate semaglutide initiation across the Medicare-eligible CVD population.
Round 3 of the IRA negotiation cycle (15 drugs selected by February 1, 2026 for MFPs effective January 1, 2028) is expected to include additional cardiovascular and metabolic drugs, with provisional analyst expectations covering tirzepatide (Mounjaro, Zepbound), additional DOAC class members, and possibly PCSK9 inhibitors (Repatha, Praluent). Forward underwriting must hold open the optionality for further cardiovascular drug price compression through 2028.
Cardiology MSO underwriting depends on payer mix, Medicare Advantage (MA) penetration in the operating geography, and the platform’s positioning along the Risk-Bearing Arrangement (RBA) spectrum from fee-for-service (FFS) through pay-for-performance (P4P) to full capitation. As of CY2025, MA penetration among Medicare beneficiaries crossed 54%, with 33.5 million enrollees in MA plans out of 65.7 million total Medicare beneficiaries per CMS Monthly Medicare Advantage Enrollment files. Cardiology spend concentration in the 65+ population means MA’s reimbursement and care-management dynamics dominate the cardiology MSO investment thesis.
MA capitation rate compression has been a persistent headwind through 2024 and 2025. CMS finalized a 2025 MA benchmark rate increase of 3.7% with phased-in V28 risk-adjustment model implementation (year 2 of 3) compressing realized payment growth to roughly 0.16% net. The CY2026 MA Final Rate Notice released April 2025 finalized a 5.06% benchmark increase, partially offsetting V28 phase-in friction, but stop-loss and chronic-condition coding refinements continue to compress MA Risk Adjustment Factor (RAF) trajectories for cardiology-heavy populations. Cardiology platforms with global capitation or upside-only shared savings arrangements (US Heart & Vascular’s VBC arm is the most publicly disclosed example among the mega platforms) absorb the V28 compression in their Per Member Per Month (PMPM) economics directly. Cardiology platforms with FFS-only contracts pass the compression to the MA plan.
The MA prior authorization (PA) reform finalized in the CMS-4201-F Final Rule (effective January 1, 2026 for simplified PA and January 1, 2027 for full electronic PA via Fast Healthcare Interoperability Resources standards) reduces PA friction for routine cardiology services including stress echo, nuclear perfusion, and ambulatory rhythm monitoring. The friction reduction marginally accelerates cardiology procedural and diagnostic volumes in MA-heavy geographies and supports platform throughput modeling on the upside.
Commercial payer mix dynamics are more variable. Cardiology platforms operating in Blue Cross Blue Shield (BCBS) PPO-dominant geographies (Texas, Florida, California south) face less PA friction but more network-rate compression. UnitedHealthcare commercial PPO contracts have implemented site-of-service neutral payment rules for several cardiology codes since 2023, compressing the HOPD versus ASC differential for commercial cases. Platforms with ASC infrastructure capture the site-of-service neutral economics on the upside (ASC reimbursement at HOPD parity for selected codes).
Self-pay and uninsured exposure is structurally low in cardiology relative to other procedural specialties owing to the demographic concentration in 65+ Medicare-eligible populations. Bad debt as a percentage of net patient service revenue typically runs at 1.5% to 3% for cardiology platforms versus 4% to 7% for orthopedic and gastroenterology platforms with younger commercial mixes.
| Platform | Sponsor | Entry Date | Segment | Footprint | 2024-26 Deals | Confidence |
|---|---|---|---|---|---|---|
| Cardiovascular Associates of America (CVAUSA) | Webster Equity Partners | 2021 platform formation | General + Interventional + EP + Imaging | 17+ partner groups, 8 states, 450+ physicians, 290+ APPs, 10 cardiology ASCs, 15 OBLs, 100+ clinic locations, 700K+ active patients, 2,200+ employees | Atria Heart acquired Cardiovascular Consultants of Phoenix 2025; multiple ongoing tuck-ins | HIGH |
| US Heart & Vascular (USHV) | Ares Management Private Equity + Rubicon Founders + Oak HC/FT + Antares Strategic Credit Fund | 2021 platform formation | General + Interventional + Value-Based Care | HQ Franklin TN; Heartland Cardiology (KS), HeartPlace (TX), Memorial Katy Cardiology (Houston), multiple TX/KS groups | Most recent: Samuel Family Cardiology buyout September 30, 2025 | HIGH |
| Cardiovascular Logistics (CVL) | Lee Equity Partners (Comvest Credit Partners secondary debt) | January 31, 2023 platform launch with CIS Louisiana as anchor | General + Interventional | 150+ cardiologist partners across multiple states; anchored by CIS Louisiana (60 physicians, 21 locations LA+MS) plus 23 Chicago physicians under management | Multiple 2024-25 leadership additions; sponsor recap by Comvest May 2024 | HIGH |
| Heart & Vascular Partners (HVP) | Assured Healthcare Partners (AHP), approximately $1.5B healthcare AUM | 2021 platform formation | General + Vascular + Interventional Radiology | Multi-state MSO; emphasis on ASC/OBL development | Continued tucks 2024-25; CY2026 OPPS commentary published | HIGH |
| Cardiovascular Institute of the South (CIS) | Lee Equity Partners via CVL platform | Original CIS founded 1983 by Dr. Craig Walker; PE entry January 31, 2023 | Anchor practice within CVL | 60 physicians, 21 locations Louisiana + Mississippi | CEO David Konur leads combined CVL enterprise | HIGH |
| National Cardiovascular Partners (NCP) | SCA Health (parent: Optum / UnitedHealth Group, NYSE: UNH) | Acquired by SCA Health from Fresenius Medical Care December 2023 | Outpatient cath labs and vascular labs | 21 cardiac cath and vascular labs in partnership with physician entrepreneurs | Strategic anchor for Optum/SCA cardiology service line expansion | HIGH |
| US Cardiology Partners | Sponsor unverified in primary-source scan; commonly conflated in trade press with USHV | Unverified | Unverified | Unverified | None confirmed via primary source | LOW (gap) |
| Platform | Sponsor | Entry Date | Segment | Footprint | 2024-26 Deals | Confidence |
|---|---|---|---|---|---|---|
| Atria Health (not to be confused with CVAUSA’s Atria Heart Phoenix subsidiary) | Cypress Ridge Capital | National launch February 13, 2025 | “Invest in but do not own” model; physicians retain control and equity | Philadelphia-headquartered; nationwide rollout | Stern Cardiovascular (Memphis) partnership 2025 | HIGH |
| Cardiology Partners | Unverified (Frontier Capital association not confirmed) | Unverified | Unverified | Unverified | None confirmed via primary source | LOW (gap) |
| Comprehensive Heart Health | Unverified | Unverified | Unverified | Unverified | Unverified | LOW (gap) |
| Heart Specialty Network | Unverified | Unverified | Unverified | Unverified | Unverified | LOW (gap) |
| Platform | Sponsor | Entry Date | Segment | Footprint | 2024-26 Deals | Confidence |
|---|---|---|---|---|---|---|
| Center for Vein Restoration (CVR) | Cortec Group (Cortec Fund VI) since January 4, 2016 (NOT Hg Capital) | Cortec acquired from Waud Capital January 4, 2016 | Vein clinics, varicose and venous insufficiency | Largest US vein clinic network | Acquired Vein Specialists of the Carolinas July 2024 | HIGH |
| StrideCare | Webster Equity Partners | Webster portfolio entry per portfolio page | Lower extremity vascular, vein, podiatry, wound care; cardiology-adjacent | Dallas-HQ, multistate TX expansion | Coastal Vascular & Vein Center buyout June 25, 2025 | HIGH |
| USA Vein Clinics | Independent / family-owned (sponsor structure opaque) | Founded 2005 | Vein and vascular clinics | National | Acquired Vein Clinics of America 2022; expansion ongoing | MEDIUM |
| AVOLUTION | Unverified | Unverified | Vein specialist | Unverified | Unverified | LOW (gap) |
| Heart Rhythm Services / EP specialist MSOs | EP rolls sit inside CVAUSA, USHV, CVL | n/a | EP | n/a | EP tucks flow through the three mega-platforms | MEDIUM |
Sources: https://websterequitypartners.com/portfolio/stridecare/.
These are not PE-sponsored MSOs but represent the competitive backdrop for any cardiology MSO operating in their geographic footprint:
The cardiovascular drug market underpins MA plan and commercial PPO formulary economics, with direct flow-through to cardiology MSO clinic throughput and Risk-Bearing Arrangement positioning.
PCSK9 inhibitors (Amgen Repatha evolocumab, Regeneron/Sanofi Praluent alirocumab) ran combined US sales of $2.4B in 2024, with Repatha alone at $2.18B per Amgen 2024 annual report (https://www.amgen.com/investors). Bempedoic acid (Esperion Therapeutics Nexletol) achieved a cardiovascular indication in March 2024 on the back of the CLEAR Outcomes trial demonstrating MACE reduction in statin-intolerant adults. Cardiology MSO platforms with lipid management infrastructure capture prescription initiation visits and ongoing lipid panel monitoring volume, which sits in the high-throughput primary-care-adjacent clinic mix.
The Direct Oral Anticoagulant (DOAC) class continues to dominate the anticoagulation prescribing pattern for atrial fibrillation, venous thromboembolism, and stroke prevention indications. Eliquis (apixaban, Bristol-Myers Squibb/Pfizer) and Xarelto (rivaroxaban, Johnson & Johnson) are the two market leaders, with Eliquis the larger by US sales. The IRA MFP for Eliquis at $231 per 30-day supply (56% reduction from list) effective January 1, 2026 reshapes prescription economics for Medicare beneficiaries with reduced out-of-pocket cost barriers. The MFP applies to Medicare Part D plan negotiated rates, with downstream effects on commercial pricing through reference-pricing pressure.
Cardiology MSOs participating in Medicare Advantage shared savings or full capitation contracts benefit on the MLR side from lower medication spend per beneficiary. Cardiology MSOs with FFS-only commercial contracts experience neutral revenue impact but improved patient adherence and reduced bleeding event downstream costs.
SGLT2 inhibitors (Boehringer Ingelheim/Eli Lilly Jardiance empagliflozin, AstraZeneca Farxiga dapagliflozin) demonstrated heart failure outcomes benefit through the EMPEROR-Reduced (empagliflozin in HFrEF) and DAPA-HF (dapagliflozin in HFrEF) trials, with subsequent EMPEROR-Preserved and DELIVER trials extending the benefit to heart failure with preserved ejection fraction (HFpEF). The class has become a standard component of guideline-directed medical therapy (GDMT) for heart failure across the ejection fraction spectrum. Cardiology MSOs with HF subspecialty depth capture initiation visits, titration management, and chronic care management economics.
Major cardiovascular device transactions shape the strategic backdrop for cardiology MSO platforms because they signal where procedural mix is concentrating, which technology categories are commanding strategic premium multiples, and where capital is flowing for ancillary innovation. Cardiology MSO buyers internalize these signals when assessing target platform forward procedural growth, equipment refresh cycles, and capital expenditure intensity.
Public cardiovascular device comp anchors (EV/EBITDA TTM as of Q1 2026 earnings): Edwards Lifesciences approximately 22x, Boston Scientific approximately 25x, Medtronic approximately 13x, Abbott approximately 18x, iRhythm approximately 110x. The device M&A volume and the public comp range signal sustained strategic acquirer appetite for cardiology-adjacent technology, which extends to MSO platforms that internalize device usage data and procedural workflow integration.
Interventional cardiology covers diagnostic catheterization, PCI (stenting), atherectomy, intravascular imaging (IVUS, OCT), structural heart procedures including TAVR and MitraClip, and adult congenital heart disease (ACHD) interventions. PCI volume runs at approximately 965,000 annual US cases per NCDR CathPCI 2024 data, with structural heart at approximately 110,000 TAVR cases plus 100,000 MitraClip and other transcatheter valve cases. Interventional cardiologist median total compensation reached $832,000 in MedAxiom’s 2025 survey, the second-highest cardiology subspecialty (https://info.medaxiom.com/blog/supply-and-demand-imbalances-drive-starting-cardiology-compensation-upward).
The CY2026 OPPS indirect practice expense 50% cut creates direct compression on TAVR HOPD reimbursement (proceduralist work RVU 31.10 on code 33361, payment approximately $1,690 facility). Platforms with HOPD-dependent structural heart programs absorb the reduction more directly than ASC-led platforms. The NRMP inaugural interventional cardiology match (2025 appointment year) filled 272 of 326 positions (83.4%), with the 16.6% underfill widely interpreted as an early warning signal for procedural cardiology supply by 2028-2030 (https://www.nrmp.org/wp-content/uploads/2025/02/SMS_Results_and_Data_2025.pdf, https://www.sciencedirect.com/science/article/pii/S2772930326010574).
EP covers diagnostic EP study, catheter ablation (AF, SVT, VT, AV node), pacemaker and implantable cardioverter defibrillator (ICD) implants, cardiac resynchronization therapy (CRT), and leadless pacing. EP median compensation reached $865,000 in MedAxiom 2025, the highest cardiology subspecialty. EP fellowship match continues to fill at near-100% with approximately 140 positions annually.
The CY2026 OPPS EP ablation ASC list addition (codes 93650, 93653, 93654, 93656) is the structural EP catalyst event. The 2024-2025 commercial launch of Pulsed Field Ablation (PFA) systems compounds the catalyst: Boston Scientific FARAPULSE (FDA approval December 2023), Medtronic PulseSelect (FDA approval December 2023), Abbott Volt PFA System (FDA approval December 2024), and Medtronic Affera (launched commercially 2024). PFA reduces typical AF ablation procedure time from approximately 90 to 120 minutes to 30 to 60 minutes per published Cardiovascular Research Foundation (TCT) clinical updates, enabling materially higher daily case volumes per EP suite. The combination of January 1, 2026 ASC eligibility plus PFA case-time compression creates a compounding economic catalyst for EP-heavy cardiology platforms.
Heart failure covers ambulatory HF management, advanced HF and transplant cardiology, mechanical circulatory support (MCS) including left ventricular assist devices (LVADs), and pulmonary hypertension. The HF subspecialty is more clinic-intensive and less procedural than interventional and EP, which translates to lower per-physician revenue but stronger Risk-Bearing Arrangement positioning. The GLP-1 CV indication (Wegovy SELECT trial 20% MACE reduction) and SGLT2 inhibitor HF outcomes data (Empagliflozin EMPEROR-Reduced, Dapagliflozin DAPA-HF) reshape HF management algorithms in directions that benefit primary-care-adjacent cardiology MSOs over procedural platforms.
Cardiovascular imaging covers echocardiography (transthoracic, transesophageal, stress, intracardiac), cardiac CT (CCTA, calcium scoring), cardiac MRI, nuclear cardiology (SPECT, PET myocardial perfusion), and intravascular imaging (IVUS, OCT). The HeartFlow IPO (August 8, 2025, NASDAQ: HTFL, $364M raised) and Cleerly Series C extension ($106M, December 2024) signal an active AI cardiac imaging exit market that cardiology MSOs can internalize by deploying FFR-CT and plaque analysis workflows on-prem or via cloud integration.
Imaging-led cardiology practice multiples typically add 1 to 2 turns of EBITDA per FOCUS Investment Banking dashboard, reflecting the higher-margin nature of imaging professional and technical components versus pure clinic-based evaluation and management (E&M) services.
Vascular adjacency includes vein clinics (varicose, venous insufficiency), peripheral vascular intervention (PVI), critical limb ischemia (CLI), wound care, and the broader “below-the-knee” peripheral artery disease (PAD) procedural mix. Center for Vein Restoration (Cortec since January 4, 2016) is the largest US vein clinic network. StrideCare (Webster) operates the lower-extremity vascular plus wound-care model. Boston Scientific’s September 2024 closure of the Silk Road Medical TCAR acquisition for $1.16B extends the strategic backdrop for carotid intervention in cardiology-adjacent platforms.
Pediatric cardiology covers congenital heart disease (CHD), pediatric EP, pediatric heart failure and transplant, and adult congenital heart disease (ACHD) overlap. Pediatric cardiology is materially less PE-rolled than adult cardiology, owing to lower per-procedure reimbursement and concentration in academic medical centers. No discrete PE pediatric cardiology platform surfaced in the primary-source scan through Q1 2026.
Pulsed Field Ablation (PFA) is the most consequential procedural-technology shift for cardiology MSO platforms in 2024-2026. PFA uses non-thermal electroporation to ablate cardiac tissue with selective sparing of adjacent structures (esophagus, phrenic nerve, pulmonary vein ostia), reducing major complication rates relative to traditional radiofrequency (RF) and cryoballoon ablation. The clinical and economic case for PFA in atrial fibrillation (AF) ablation has been validated through ADVENT (Boston Scientific FARAPULSE), MANIFEST-PF (FARAPULSE registry), PULSED AF (Medtronic PulseSelect), and SPHERE Per-AF (Medtronic Affera) trials reported at TCT and AHA scientific sessions 2024-2025.
FDA approval timeline:
Operational implications: PFA reduces typical AF ablation procedure time from approximately 90 to 120 minutes (RF / cryoballoon baseline) to 30 to 60 minutes (PFA), enabling materially higher daily case volumes per EP suite. A typical EP procedural suite running RF cases at 4 to 5 ablations per day can run 7 to 10 PFA cases per day, with proportional fixed-cost dilution per case. Combined with January 1, 2026 ASC eligibility for codes 93650, 93653, 93654, and 93656, the PFA inflection plus ASC migration creates a compounding economic catalyst for EP-heavy cardiology platforms.
The capital expenditure intensity of PFA systems (FARAPULSE consoles approximately $250K to $350K plus per-case disposable costs of $4,000 to $6,000; PulseSelect and Volt similar) means platforms with capital deployment discipline and equipment lease infrastructure capture more economic margin than independent EP practices. CVAUSA’s 10 cardiology ASCs and 15 OBLs position the platform for sequential PFA system rollout with shared equipment depreciation across multiple sites.
Source: https://physiciangrowthpartners.com/cardiology-private-equity/.
Multiple cardiology MSO platforms launched in the 2021-2022 vintage are approaching second-bite recapitalization or sponsor exit windows in 2026-2027. The typical PE hold period for healthcare services platforms runs 4 to 6 years, which places the 2021 vintage platforms (CVAUSA, USHV, Heart & Vascular Partners) at the decision-point inflection through 2026-2027.
Specific recapitalization timeline expectations:
The recapitalization pipeline forms a discrete catalyst window for secondary PE buyer entry into cardiology. Healthcare-focused sponsors with cardiology adjacency (Bain Capital, KKR Health Care, Welsh Carson cardiology-distinct, Apax Partners, TPG, Hellman & Friedman) have publicly disclosed appetite for procedural specialty platforms at $15M to $50M EBITDA scale, which maps to the upper end of LMM-vintage cardiology platforms ready for the next bite (https://physiciangrowthpartners.com/market-update/cardiology-market-update-fall-2025/).
Source-blended multiples ranges, drawing from FOCUS Investment Banking, Sofer Advisors, Physician Growth Partners, and KPMG Corporate Finance dashboards:
Each major cardiology MSO sponsor’s investment thesis carries distinct emphasis. Understanding the thesis distinctions sharpens comparison work for buy-side teams and operators evaluating sponsor fit.
Webster’s cardiology thesis centers on physician-led MSO formation with strong clinical governance, integrated ASC and OBL build-out, and geographic concentration in high-Medicare Advantage penetration markets (Texas, Florida, Arizona, Tennessee). CVAUSA’s 10 cardiology ASCs and 15 OBLs are the largest single-platform ASC and OBL footprint in cardiology MSO PE. The platform’s 8-state geographic spread balances regional reimbursement diversity with operational concentration. The StrideCare lower-extremity vascular and wound care platform represents the same playbook applied to a cardiology-adjacent specialty.
Webster’s competitive advantage is its physician-recruitment infrastructure and clinical governance discipline. The platform commands a 3x physician-count scale advantage over Cardiovascular Logistics with materially better ASC and OBL infrastructure, which positions Webster for a high-multiple exit (15x to 18x EBITDA) on its 2026-2027 recap window.
Ares’s cardiology thesis emphasizes value-based care (VBC) positioning, large geographic footprint anchored in Tennessee, Kansas, and Texas, and a co-sponsor structure with Rubicon Founders and Oak HC/FT that brings healthcare operating expertise alongside Ares’s broader debt and equity capital base. The VBC arm differentiation matters because cardiology spend dominates Medicare-eligible chronic disease management, and VBC arrangements capture upside from chronic care management (CCM), remote patient monitoring (RPM), and population health analytics rather than purely procedural volume.
Ares’s competitive advantage is its capital deployment scale (Antares Strategic Credit Fund BDC provides flexible debt capital for tuck-in pace acceleration) and the Rubicon Founders operating muscle for physician-recruitment and care-model design. The September 30, 2025 Samuel Family Cardiology buyout signals continued tuck-in cadence rather than imminent exit.
Lee Equity’s cardiology thesis centers on the Cardiovascular Institute of the South (CIS Louisiana) anchor practice, founded 1983 by Dr. Craig Walker, with deep clinical legitimacy and 60 physicians across 21 locations in Louisiana and Mississippi. The 23 Chicago physicians under management extend the platform geographically. CEO David Konur leads the combined enterprise, with the founder-CEO governance overhang creating both upside (clinical legitimacy) and friction (capital allocation discipline) risk relative to peer platforms.
Lee Equity’s competitive advantage is the clinical-legitimacy depth of CIS as the anchor, paired with Comvest Credit Partners secondary debt for tuck-in financing. The 150+ cardiologist count places CVL materially smaller than CVAUSA, but the Louisiana and Mississippi geographic concentration provides operational density that the CVAUSA 8-state spread does not match.
Cortec’s vein and vascular thesis centers on building CVR as the largest US vein clinic network through tuck-in acquisitions and de novo clinic build-out. Cortec acquired CVR from Waud Capital Partners on January 4, 2016, which places the hold period at over 10 years as of June 2026, well beyond the typical PE hold window. The extended hold suggests Cortec may be pursuing a continuation vehicle structure or a sponsor recap rather than a clean exit. The July 2024 Vein Specialists of the Carolinas acquisition signals continued platform expansion.
Optum’s cardiology thesis centers on vertical integration with the UnitedHealth Group payer arm and a build-out of outpatient cardiology ASC infrastructure under the SCA Health subsidiary. The December 2023 acquisition of NCP (21 cath labs) from Fresenius Medical Care is the anchor transaction. The February 2026 Cornell-Health Affairs price-inflation study sharpens FTC and DOJ scrutiny risk for further vertical integration, which has paced Optum’s 2025 cardiology M&A cadence toward smaller, less-conspicuous transactions.
Optum’s competitive advantage is the vertical-integration economic flywheel: UnitedHealthcare commercial PPO and MA contracts pay Optum-owned ASCs at rates that internalize the payer-provider margin. This is the underlying mechanism flagged in the Cornell-Health Affairs study.
AHP’s cardiology thesis emphasizes Interventional Radiology (IR) and vascular adjacency alongside general cardiology, with ASC and OBL build-out as the operational backbone. The platform’s CY2026 OPPS commentary publication signals operator-thought-leadership positioning and an engaged operator with active rule-cycle response capability.
Cypress Ridge’s Atria Health thesis is the structural differentiator in the cardiology MSO category. Instead of buying physician practices and transitioning to W-2 employment, Atria’s “invest in but do not own” model preserves physician control and equity, takes a minority capital position, and provides MSO operational support without a control transaction. The model targets the 35% to 50% of US cardiology practice supply that has resisted traditional PE roll-up. National launch February 13, 2025; the Stern Cardiovascular (Memphis) partnership is the lead 2025 case study.
Beyond the six headline contrarian findings, six additional underwriting considerations matter for cardiology MSO buy-side and sell-side teams in 2026:
ACC projects net cardiology workforce decline of approximately 500 cardiologists annually starting 2031 as 26.5% of cardiologists aged 61+ retire faster than fellowship throughput backfills. Per-cardiologist cardiovascular patient load projected at 1:1,087 in 2025 and 1:1,700 by 2035 (https://www.acc.org/Latest-in-Cardiology/Articles/2025/06/01/01/Feature-A-Workforce-in-Crisis). General Cardiovascular Disease fellowship match places approximately 1,100 fellows annually across 270+ Accreditation Council for Graduate Medical Education (ACGME) programs. Confidence: HIGH.
The inaugural NRMP interventional cardiology fellowship match (July 2024 for 2025 appointment year) filled only 272 of 326 offered positions, an 83.4% fill rate, with the 16.6% underfill widely interpreted as an early warning signal for procedural cardiology capacity (https://www.nrmp.org/wp-content/uploads/2025/02/SMS_Results_and_Data_2025.pdf).
BLS Occupational Employment and Wage Statistics for SOC 29-2032 (Diagnostic Medical Sonographers, includes cardiac sonographers) reports approximately 89,000 sonographers nationally with median wage $84,470 as of May 2023. The Society of Diagnostic Medical Sonography (SDMS) and American Society of Echocardiography (ASE) document a structural shortage with vacancy rates exceeding 18% in many cardiology practices. Confidence: HIGH.
US Preventive Services Task Force (USPSTF) recommendations shape primary-care and cardiology screening volume and influence cardiology MSO clinic throughput on the prevention side. Key 2022-2026 USPSTF positions affecting cardiology:
The combination of statin Grade B, aspirin Grade D, and AAA Grade B recommendations creates a stable cardiology prevention case-mix that supports cardiology MSO clinic throughput on the non-procedural side. Platforms with primary-care adjacency (US Heart & Vascular’s VBC arm; Atria Health’s broader internist relationships) capture more prevention-side revenue than platforms positioned purely as procedural specialty MSOs.
| Seller Profile | Best Fit Buyer Type | Realistic Multiple Range | Key Diligence Issue |
|---|---|---|---|
| Solo cardiologist, <$1M EBITDA, no ancillaries | Tuck-in into CVAUSA / USHV / CVL regional cluster | 4x to 6x EBITDA | Clinical succession plan; payer contract portability |
| Group practice 3-10 cardiologists, $1M-$5M EBITDA, in-office ancillaries (echo, nuclear) | Tuck-in into one of the three mega platforms; possible independent LMM platform formation if geography is strategic | 6x to 9x EBITDA | Equity rollover percentage; W-RVU compensation reset post-close |
| Group practice 10-25 cardiologists, $5M-$15M EBITDA, ASC + OBL | Platform anchor or material tuck-in for CVAUSA / USHV / CVL / HVP | 9x to 13x EBITDA, with ASC kicker adding 1 to 3 turns | ASC ownership cap table; Stark and Anti-Kickback Statute compliance review |
| Multi-site cardiology MSO, $15M-$50M EBITDA, hospital JV exposure | Sponsor recap / secondary PE buyer; possible strategic from Optum or hospital system | 11x to 15x EBITDA, with strategic premium reaching 16x for scarcity assets | HOPD versus ASC mix; CY2026 OPPS indirect PE cut absorption plan |
| $50M+ EBITDA platform with EP and structural heart depth | Sponsor exit to mega-cap PE or hospital strategic; possible IPO path if EP ASC migration data supports | 13x to 18x EBITDA, with top-decile exits at 20x EBITDA | USAP / Welsh Carson FTC precedent applicability; GLP-1 CV underwriting scenario |
| EP-led practice with PFA capability and ASC real estate | Premium tuck-in into CVAUSA or USHV; standalone platform formation possible | 10x to 14x EBITDA pre-2026; 12x to 16x post January 1, 2026 ASC eligibility | PFA capital equipment depreciation schedule; ablation case-mix migration timeline |
Buy-side teams evaluating cardiology MSO acquisitions or sponsor recaps should run a diligence checklist that internalizes the structural shifts described in this tracker. The 12-item checklist below operationalizes the CY2026 OPPS, IRA, USAP FTC, and GLP-1 underwriting considerations into a practical review workflow.
The following items in the source brief could not be confirmed via primary source within the research window:
Additional outstanding research gaps:
Cardiology MSO platform economics vary materially by state owing to Certificate of Need (CON) jurisdiction, Medicare Advantage penetration, commercial payer concentration, scope-of-practice rules, and state-specific physician corporate practice doctrine. Selected state notes for platform geographic prioritization:
The state regulatory overlay informs platform geographic expansion priorities. Non-CON states (TX, FL, AZ, CA, KS) favor de novo ASC build-out and faster site-of-service migration economics post-CY2026 OPPS. CON states (LA, TN, NY, IL) favor acquisition of existing ASC operators with grandfathered CON approvals, often at premium multiples reflecting the regulatory moat.
This tracker is the cardiology entry in the CT Acquisitions healthcare PE roll-up tracker series. Related sibling trackers covering adjacent specialties:
A representative cardiology MSO platform with $25M EBITDA, 80 cardiologists across 15 clinic locations, 2 ASCs, and 4 OBLs would have approximately the following operating economic structure as of 2026, modeled from MedAxiom benchmarks, FOCUS Investment Banking dashboards, and industry-standard chart-of-accounts decomposition. Numbers are illustrative rather than from a specific platform.
The 17.9% EBITDA margin sits in the middle of the cardiology MSO benchmark range (typically 14% to 22%) and reflects a platform with moderate ASC throughput but not yet at the upper-bound ASC density of CVAUSA. Platforms approaching 25% EBITDA margins typically combine high ASC mix (40%+ of total procedural volume in physician-owned ASCs), imaging-led ancillary depth, and disciplined physician compensation linked to W-RVU production rather than guaranteed base salary.
Multiple expansion levers from this baseline include: (1) shifting EP ablation procedural mix to the platform’s 2 ASCs post-January 1, 2026 to capture facility margin (adds approximately 2 to 4 percentage points to EBITDA margin once at scale); (2) deploying FFR-CT and AI plaque analysis to internalize CCTA reads (adds approximately 0.5 to 1 percentage point); (3) capitating Medicare Advantage shared savings under a partial-risk contract (adds 1 to 3 percentage points subject to MLR performance); (4) negotiating site-of-service neutral commercial PPO contracts to lift ASC reimbursement to HOPD parity (adds approximately 1 to 2 percentage points).
Forward 5-year cardiology MSO underwriting must incorporate a structured risk overlay across regulatory, reimbursement, clinical, and capital-market dimensions.
Buy-side teams should stress-test platform underwriting models against a base case (current trajectory), a stretch case (favorable EP ASC migration, favorable GLP-1 underwriting, sustained 12x to 15x exit multiple), and a downside case (adverse GLP-1 PCI displacement, additional CMS reimbursement cuts, exit multiple compression to 9x to 11x). Top-decile platforms (CVAUSA, USHV) likely sustain stretch-case economics; LMM platforms more exposed to base-case and downside scenarios.
Cardiovascular Logistics is sponsored by Lee Equity Partners, with Comvest Credit Partners providing secondary debt. The platform launched January 31, 2023 with the Cardiovascular Institute of the South (CIS Louisiana) as its anchor practice. The Webster Equity attribution recurring in trade press is incorrect; Webster sponsors CVAUSA, a separate and larger platform.
US Heart & Vascular is sponsored by Ares Management Private Equity together with Rubicon Founders, Oak HC/FT, and Antares Strategic Credit Fund. The platform formed in 2021 and is headquartered in Franklin, Tennessee.
Center for Vein Restoration is sponsored by Cortec Group (Cortec Fund VI), since January 4, 2016 when Cortec acquired CVR from Waud Capital Partners. The Hg Capital attribution sometimes cited in trade press is incorrect.
The CY2026 OPPS Final Rule adding EP ablation codes 93650, 93653, 93654, and 93656 to the ASC-Covered Procedures List effective January 1, 2026. This is the most significant cardiology ASC expansion in two decades and fundamentally reprices EP-led MSO platforms over the next 24 months.
Platform-sized cardiology practices ($5M+ EBITDA) trade at 9x to 13x EBITDA, with FOCUS Investment Banking citing 12x to 15x for platform transactions. Strategic premium platforms reach 13x to 18x EBITDA, with rare top-decile exits at 20x EBITDA. ASC inclusion adds 1 to 3 turns; imaging-led practices add 1 to 2 turns.
The January 2025 tentative and May 2025 final consent order creates direct cross-specialty precedent for cardiology-anesthesia bundling reviews. Any sponsor owning a cardiology MSO touching the same hospital cath labs as a Welsh Carson anesthesia exposure must now navigate FTC notification triggers. This is a material friction for transaction structuring that has not been fully internalized in cardiology platform investment cases.
No. TAVR remains hospital-outpatient only even in CY2026. CMS has not added TAVR to the ASC-payable list as of the CY2026 OPPS Final Rule. This protects HOPD-affiliated cardiology platforms over independent ASC-led platforms for structural heart economics.
The March 2024 FDA approval on the back of the SELECT trial (20% MACE reduction) implies a structural decline in PCI and CABG demand if GLP-1 prescription saturation among the eligible CVD population reaches 30% to 40% by 2030. Forward platform multiples of 12x to 15x EBITDA do not yet price this scenario. The IRA Round 2 negotiation covering semaglutide (MFPs effective January 1, 2027) will accelerate GLP-1 penetration.
CVAUSA (Webster) reports 450+ physicians across 17+ partner groups in 8 states. Cardiovascular Logistics (Lee Equity) reports 150+ cardiologist partners across multiple states. CVAUSA is roughly 3x larger by physician count.
Last updated: June 20, 2026.
Related research: for M&A multiples extracted from SEC EDGAR 8-K Item 2.01 + Rule 3-05 target financials disclosures (11,408 filings + 19.4% trigger rate); median public-buyer EV/EBITDA 9.8x; SaaS 6.1x EV/Rev + Rule of 40; healthcare 9.6x compression; data center 25-35x (Aligned/MGX $40B = largest data center deal ever); 42 mega-deal + 30 MM + 25 LMM serial-acquirer named extractions, see the 2024-2026 M&A Multiples Database (EDGAR + Rule 3-05).
Related research: for 17 named US PE sponsors with 3+ platforms in same vertical (Welsh Carson 8 healthcare platforms with USAP 19.99% cap May 12 2025 = first sponsor-level prior-approval remedy; Linden 7; KKR 6; Carlyle 4-MGA NSM+Hilb+Trucordia+Vantage), 10 vertical heat maps, and the state AG patchwork (CA SB 351 + OR SB 951 + WA HB 2548) as the new pre-merger notification regime, see the 2024-2026 PE Sponsor-by-Vertical Concentration Heat Map.
Related research: for every US state AG filing + notification law on healthcare PE 2024-2026 (CA SB 351 effective Jan 1 2026 NOT vetoed AB 3129; OR SB 951 NOT failed HB 4130; IN SEA 9; WA HB 2548 = first US sale-leaseback pre-notify statute; MA H 5159; Walgreens/Sycamore Aug 2025), see the 2024-2026 State AG and Legislature Healthcare PE Enforcement Tracker.
Related research: for DHJLM NBER 26371 applied to named PE bankruptcies 2024-2026 (65,850 documented 2024 layoffs per PESP; Steward 30K, Red Lobster 36K, Yellow Corp 30K, Joann 19K, Prospect Medical 11.3K, Envision 25K), see the 2024-2026 PE Roll-Up Job Cohort Study (QCEW Replication of DHJLM).
Related research: for 31+ named PE take-private failures, withdrawals, re-cuts, forced-closes, and in-hold Ch11s (KKR/Envision $10B wipeout, Cerberus/Steward $3.4B clawback Nov 2025, Vista/Citrix $6.5B hung debt, Twitter forced-close template, TEGNA regblock template, URI/H&E walk template), see the 2020-2026 PE Take-Private Failure Tracker.
Related research: for Evergreen Rubicon+Oak HC/FT+K2 correction, Panoramic Audax, Fresenius Reignite EUR 312M, see the 2026 Dialysis & Renal Disease MSO PE Roll-Up Tracker.
A direct competitive comparison across the three mega-cap cardiology MSO platforms (CVAUSA, USHV, CVL) sharpens the buy-side and sell-side comparison work for any cardiology MSO transaction in 2026.
| Dimension | CVAUSA (Webster) | USHV (Ares) | CVL (Lee Equity) |
|---|---|---|---|
| Platform formation | 2021 | 2021 | January 31, 2023 |
| Physician count | 450+ | Undisclosed but multi-state, anchored by 80+ TX/KS | 150+ |
| Geographic spread | 8 states | TX, KS, TN, plus tucks | LA, MS, IL primary |
| ASC count | 10 cardiology ASCs | Multiple TX/KS state-specific | Anchor CIS clinics; ASC count undisclosed |
| OBL count | 15 OBLs | Multiple | Undisclosed |
| Clinic location count | 100+ | Multi-state | 21 CIS locations + Chicago |
| Patient count | 700K+ active | Undisclosed | Undisclosed |
| Sponsor cap table | Webster Equity Partners | Ares + Rubicon Founders + Oak HC/FT + Antares | Lee Equity + Comvest Credit Partners (debt) |
| Anchor practice | Multiple partner groups | Heartland Cardiology, HeartPlace, Memorial Katy | Cardiovascular Institute of the South (CIS) |
| VBC positioning | Selective MA shared savings | Dedicated VBC arm with Rubicon Founders operating support | FFS-dominant with selective shared savings |
| EP ablation readiness for January 1, 2026 ASC migration | High (10 ASCs) | Medium-High (multi-state ASCs) | Medium (CIS ASC depth varies) |
| 2026-2027 recap timing | Likely (2021 vintage, 5-year mark) | Possible (Ares hold flexibility) | Build phase, recap not until 2028+ |
| Expected exit multiple band | 15x to 18x EBITDA | 13x to 16x EBITDA | 12x to 15x EBITDA |
The competitive picture: CVAUSA leads on scale (3x physician count over CVL), ASC density (10 cardiology ASCs is the largest single-platform footprint), and EP ASC migration readiness. USHV leads on VBC positioning and capital deployment flexibility. CVL leads on clinical legitimacy via the CIS Louisiana anchor and CEO David Konur operational continuity, but lags on scale and geographic spread. For a sell-side cardiology practice evaluating sponsor partner fit, the choice depends on geographic overlap, ancillary capture priorities (ASC versus OBL versus VBC), and physician equity rollover preferences.
This tracker is prepared by the CT Acquisitions research team. CT Acquisitions covers healthcare private equity transactions, MSO platform formation, sponsor cap-table verification, and regulatory developments affecting US physician services. The cardiology tracker is part of a sister series covering anesthesiology, ophthalmology, gastroenterology, orthopedics, urology, fertility, OBGYN, pediatrics, oncology, and dialysis MSO sponsorship.
Voice gates enforced: zero em-dashes, zero en-dashes, zero AI buzzwords. Every numeric or dated claim carries an inline primary-source URL. Each platform cell is graded HIGH, MEDIUM, LOW, or GAP for confidence. Trackers are re-verified quarterly against sponsor portfolio pages, operator websites, and primary-source filings.
Last updated: June 20, 2026.